SCHEMBL5124112

SCHEMBL5124112

CCc1nc2cc(OC)cc(OC)c2c(=O)o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 5/20 0.50
▸ PDE3B Q13370 2/20 0.49
▸ PDE3A Q14432 2/20 0.49
▸ KDM4E B2RXH2 3/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ LMNA P02545 2/20 0.42
▸ GAA P10253 2/20 0.42
▸ HPGD P15428 2/20 0.42
▸ HSD17B10 Q99714 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ GLA P06280 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.41
▸ MAOA P21397 2/20 0.41
▸ BRD4 O60885 1/20 0.40
▸ HIF1A Q16665 1/20 0.40
▸ EPAS1 Q99814 1/20 0.40
▸ ABCB1 P08183 1/20 0.38
▸ ABCG2 Q9UNQ0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5127383 0.89 ELANE (0.48) ELANEPDE3BPDE3AKDM4EALDH1A1
SCHEMBL5127478 0.87 ELANE (0.46) ELANEPDE3BPDE3AKDM4EALDH1A1
SCHEMBL5117205 0.85 ELANE (0.47) ELANEPDE3BPDE3AKDM4EALDH1A1
SCHEMBL5127361 0.81 ELANE (0.61) ELANEPDE3BPDE3AKDM4EALDH1A1
SCHEMBL5121567 0.77 ELANE (0.49) ELANEPDE3BPDE3AKDM4EALDH1A1
SCHEMBL10661040 0.71 ELANE (0.52) ELANEKDM4EALDH1A1MEN1KMT2A
SCHEMBL10748455 0.70 ELANE (0.60) ELANEPDE3BPDE3AALDH1A1
SCHEMBL5121850 0.70 PDE3B (0.47) ELANEPDE3BPDE3AKDM4EALDH1A1
SCHEMBL7696835 0.70 ALDH1A1 (0.61) PDE3BPDE3AKDM4EALDH1A1LMNA
SCHEMBL10661468 0.69 ELANE (0.76) ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7381730-B2 3-arylquinazoline derivatives as selective estrogen receptor beta modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2008-06-03 — — US disclosed
US-7381730-B2 3-arylquinazoline derivatives as selective estrogen receptor beta modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2008-06-03 — — US disclosed
US-7381730-B2 3-arylquinazoline derivatives as selective estrogen receptor beta modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2008-06-03 — — US disclosed
US-20030220227-A1 3-Arylquinazoline derivatives as selective estrogen receptor beta modulators BRISTOL-MYERS SQUIBB COMPANY 2003-11-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220227-A1 3-Arylquinazoline derivatives as selective estrogen receptor beta modulators ESR2, ESRRA, ESRRG ELANE 2474/4885PDE3B 1751/4885PDE3A 1944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback